PADI4 and plasma cell myeloma: tried a novel PAD4‐specific inhibitor BMS‐P5 in myeloma‐bearing mice and found a more substantial effect on the inhibition of NETosis compared with other nonselective PAD inhibitors CI‐amidine and GSK‐484.